Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT

Inclusion Criteria: * Patients with a clear diagnosis of hematologic disease, weighing ≥30kg, aged 18-60, of any gender and race; * Willing to undergo haploidentical hematopoietic stem cell transplantation; * Voluntarily participate in this study; * Each subject must sign an informed consent form (ICF) indicating their understanding of the purpose and procedures of the study, and their willingness to participate. Considering the patient 's condition, if the patient' s signature is unfavorable for disease treatment, the informed consent form should be signed by the legal guardian or the patient 's immediate family member. Exclusion Criteria: * Those with severe organ dysfunction or diseases, such as heart, liver, kidney, and pancreatic diseases; * Patients who cannot tolerate CD25 monoclonal antibody treatment; * Subjects and/or authorized family members who refuse allo-HSCT treatment; * Any life-threatening diseases, physical conditions, or organ system dysfunctions that the researcher believes may jeopardize the safety of the subject and pose unnecessary risks to the study; drug dependence; uncontrolled mental illness in subjects; cognitive dysfunction; * Those who have participated in other similar clinical studies within the past 3 months; * Those deemed unsuitable for inclusion by the researcher (such as patients expected to be unable to adhere to treatment due to financial issues, etc.).